Sorafenib-Induced Autophagy Promotes Glycolysis by Upregulating the p62/HDAC6/HSP90 Axis in Hepatocellular Carcinoma Cells

Sorafenib has attracted much attention as the first drug approved by the FDA for the treatment of advanced hepatocellular carcinoma (HCC). Because of the drug tolerance, the overall outcomes were far from satisfactory. Current studies suggest that changes in glucose metabolism induced by sorafenib a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xiaoyu, Tian, Rui, Sun, Jicheng, Zhao, Yuanxin, Liu, Buhan, Su, Jing, Li, Minghua, Sun, Wei, Xu, Xuesong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888828/
https://www.ncbi.nlm.nih.gov/pubmed/35250553
http://dx.doi.org/10.3389/fphar.2021.788667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888828/
https://www.ncbi.nlm.nih.gov/pubmed/35250553
http://dx.doi.org/10.3389/fphar.2021.788667

Ejemplares similares